I+Med is a pharmaceutical laboratory and manufacturer specializing in the development of biomedical solutions, particularly in the area of controlled release and smart nanohydrogels. Founded in 2013 and headquartered in Spain, the company has positioned itself as a world-leading cooperative in the advancement of intelligent nanohydrogels and controlled release systems for active substances and drugs.
The laboratory, situated in Alava (Basque Country), is dedicated to both developing and manufacturing its own products and facilitating third-party developments under its controlled release technologies. One of its key offerings is the exclusive ADAPTEK technology, which enables customised developments for the encapsulation of active molecules or drugs through intelligent nanohydrogels with controlled release capabilities.
The company's most recent investment, a €71.43K grant received on 01 June 2018, was secured from the EASME - EU Executive Agency for SMEs.
Funding Stage | Amount | No. Investors | Investors | Date |
---|---|---|---|---|
Grant | €71.43K | 1 | EASME - EU Executive Agency for SMEs | 01 Jun 2018 |
No recent news or press coverage available for I+Med.